Targeting colon cancer cells with genistein-17.1A immunoconjugate.

Michelle S. Gentile*, Chenthamarakshan Vasu, Albert Green, Genoveva Murillo, Tapas K. Das Gupta, Andreas I. Constantinou, Bellur S. Prabhakar, George I. Salti

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


We have shown that genistein, a major component of soy, has anti-colon cancer effects in vitro. These effects are attainable at high concentrations that are difficult to achieve in the serum. The purpose of this study was to enhance the activity of genistein against colon cancer cells by coupling it to 17.1A. The monoclonal antibody 17.1A recognizes an epithelial membrane antigen that is overexpressed in colon cancer. Synthesis of Gen-17.1A was achieved by photochemical conjugation using sulfa-SANPAH. Its purity was evaluated by SDS-PAGE. Binding of Gen-17.1A to SW-620 and HT-29 cells was shown using flow cytometry. Internalization was demonstrated by FITC-labeling. Gen-17.1A induced apoptosis in colon cancer cells as evidenced by the acridine orange/ethidium bromide staining method. Gen-17.1A significantly inhibited colon cancer cell growth in vitro and in vivo. Our findings suggest that conjugating genistein to 17.1A monoclonal antibody enhances its effects against colon cancer cells.

Original languageEnglish (US)
Pages (from-to)955-959
Number of pages5
JournalInternational journal of oncology
Issue number5
StatePublished - May 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Targeting colon cancer cells with genistein-17.1A immunoconjugate.'. Together they form a unique fingerprint.

Cite this